News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Compugen Ltd. (CGEN) Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy


10/31/2012 7:33:37 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN), announced today the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy. These new candidates have been shown to be expressed in multiple types of tumors and were shown to have an immunomodulatory activity in affecting both innate and adaptive immune responses, thus providing the potential for an efficient and targeted approach in cancer treatment. By offering a different mode of action from Compugen's other immune checkpoint candidates, these molecules further broaden the scope of the Company's Pipeline Program for monoclonal antibody treatment of cancer.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES